secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001437749-25-014405
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal
--------------------------------------------------------------------------------

- BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.
- Norovirus program: all 60 participants enrolled in under 2 months; topline data expected mid-2025.
- Cost reductions including workforce cuts extended cash runway into 2026; seeking additional non-dilutive funding.
- Annual meeting May 21, 2025; board seeks reverse stock split approval to avoid Nasdaq delisting; ISS and Glass Lewis recommend FOR.
- Q1 2025 earnings call scheduled for May 13, 2025; webcast at Citizens Life Sciences Conference on May 7.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/0001437749-25-014405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/vxrt20250503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer